Recombinant Human LRFN5 Fc Chimera Protein, CF

Catalog # Availability Size / Price Qty

SAVE +FREE SHIPPING with ACADEMIA23 (See Promo Details)

Recombinant Human LRFN5 Fc Chimera Protein Bioactivity
1 Image
Product Details
Supplemental Products

Recombinant Human LRFN5 Fc Chimera Protein, CF Summary

Product Specifications

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Measured by its binding ability in a functional ELISA. When Recombinant Human LRFN5 Fc Chimera is used at 1 μg/mL, the concentration of Recombinant Human LAR that produces 50% optimal binding response is 1.5-9 μg/mL.
Human embryonic kidney cell, HEK293-derived human LRFN5 protein
Human LRFN5
Accession # Q96NI6
N-terminus C-terminus
Accession #
N-terminal Sequence
No results obtained. Gln18 inferred from enzymatic pyroglutamate treatment revealing Ile19
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
83 kDa
90-107 kDa, reducing conditions

Product Datasheets

You must select a language.



Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.


Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity Recombinant Human LRFN5 Fc Chimera Protein Bioactivity View Larger

When Recombinant Human LRFN5 Fc Chimera (Catalog # 9385-SA) is used at 1 µg/mL, 100 µL/well, Recombinant Human LAR (Catalog # 9377-PF) binds with an ED50 of 1.5-9 µg/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Background: LRFN5

Synaptic adhesion-like molecule 5 (SALM5; also leucine-rich repeat and fibronectin type-III domain-containing protein 5 (LRFN5)) is an approximately 90 kDa member of the SALM family of type I transmembrane glycoproteins (1). LRFNs comprise a family of synaptic adhesion molecules consisting of five members, each containing of an extracellular domain (ECD) of six leucine-rich repeats (LRR), an IgC2-like domain, and a fibronectin type-III domain, tandemly aligned in that order (1, 2).  LRFN-3 and -5 lack a C-terminal intracellular PDZ binding domain, which is conserved among LRFN-1, 2 and 4. Mature human LRFN-5 shares 99% amino acid sequence identity with mature mouse LRFNs. LRFN-5, like the other LRFNs, promotes neurite outgrowth as well as playing a role in neuroinflammation (3, 4). LRFN-5 is expressed in the brain and is capable of inducing presynaptic differentiation (5). Reduced expression of LRFN-5 has been associated with autism spectrum disorders and schizophrenia (6, 7). LAR family receptor protein tyrosine phosphatases (LAR-RPTPs) have been identified as novel ligands of LRFN-5 that mediates LRFN-5 dependent presynaptic differentiation in a splicing- dependent manner. LRFN-5 interacts directly with the Ig domain of LAR-RPTPs. The postsynaptic LRFN-5 promotes synapse development by trans-synaptically interacting with presynaptic  LAR-RPTPs which is important for the regulation of excitatory synaptic strength (8).

  1. Morimura, N. et al. (2006) Gene 380:72.
  2. Wang, C.-Y. et al. (2006) J. Neurosci. 26:2174.
  3. Wang, P.Y. et al. (2008) Mol. Cell. Neurosci. 39:83.
  4. Yuwen, Z. et al. (2106) Sci Adv. Apr;2(4).
  5. Choi, Y. et al. (2016) Sci Adv. Apr; 2(4).
  6. de Bruijn D.R.H. et al. (2010) Mol Syndromol 46.
  7. Xu, B. et al. (2009) PNAS 106:16746.
  8. Choi, Y. (2016) Sci Rep. 6:26676.
Long Name
Leucine-rich Repeat and Fibronectin Type III Domain Containing 5
Entrez Gene IDs
145581 (Human); 238205 (Mouse); 314164 (Rat)
Alternate Names
C14orf146; chromosome 14 open reading frame 146; DKFZp686G0210; fibronectin type III, immunoglobulin and leucine rich repeat domains 8; FIGLER8; leucine rich repeat and fibronectin type III domain containing 5; leucine-rich repeat and fibronectin type-III domain-containing protein 5; LRFN5; SALM5; SALM5FLJ30803


No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reconstitution Buffers

Reviews for Recombinant Human LRFN5 Fc Chimera Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human LRFN5 Fc Chimera Protein, CF and earn rewards!

Have you used Recombinant Human LRFN5 Fc Chimera Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review